English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
The first plenary session, “’New Deal’ for Healthcare Systems—Mission Inspirational, Impossible, or Inevitable?,” is scheduled for Monday, 16 November 2020. Scientific advances in the understanding of disease biology and healthcare technologies have led to an increasing number of technological innovations. A panel of health economists, policy makers, and industry experts will address the concept of sharing the value of innovation. Panelists include:
- Moderator: Paola Testori Coggi; formerly with European Commission and Italian Medicines Agency; Milan, Italy
- Natasha Azzopardi-Muscat, MD, PhD; World Health Organization Europe; Copenhagen, Denmark
- Nathalie Moll; European Federation of Pharmaceutical Industries and Associations; Brussels, Belgium
- Fabio Pammolli; Politecnico di Milano; Milan, Italy
- Jack Scannell, PhD; JW Scannell Analytics Ltd; Edinburgh, Scotland, UK
The second plenary session, “Patient and Public Involvement in Healthcare Decision Making: Are We Maximizing Opportunities?,” is scheduled for Tuesday, 17 November 2020. This session will examine the urgent need for a more holistic and meaningful approach to citizen involvement in healthcare decision making. Experts will discuss opportunities for different thinking and explore options beyond currently practiced patient/public involvement a high level of resource allocation in healthcare. Panelists include:
- Moderator: Bettina Ryll, MD, PhD; Melanoma Patient Network Europe; Uppsala, Sweden
- Nathalie Bere, MSc; European Medicines Agency; Amsterdam, The Netherlands
- Yann Le Cam, MBA; EURORDIS; Paris, France
- Axel Mühlbacher, PhD; Hochschule Neubrandenburg; Neubrandenburg, Germany
The third plenary session, “Much Ado About Little: Dealing with Limited RCT Evidence for Early HTA and Reimbursement Decisions,” is scheduled for Wednesday, 18 November 2020. This session will focus on the approval of innovative drugs with little or no randomized controlled trial (RCT) evidence. Panelists include:
- Moderator: Mark Sculpher, PhD; University of York; York, England, UK
- Sylwia Bujkiewicz, PhD; University of Leicester; Leicester, England, UK
- Eva Susanne Dietrich, MD; Institute for Evidence-Based Positioning in the Healthcare Sector, University of Bonn, Pharmaceutical Institute; Bonn, Germany
- Stephen Palmer, PhD; University of York; York, England, UK
- Uwe Siebert, MD, MPH, MSc, ScD; University for Health Sciences, Medical Informatics and Technology, Harvard Chan School of Public Health; Tirol, Austria
In addition to the plenary sessions, Virtual ISPOR Europe 2020 will feature a wide variety of more than 40 live sessions, including spotlight sessions on regulatory collaboration as it relates to COVID-19, the credibility of real-world evidence, and methods for modeling treatment sequencing. Virtual conference sessions will be available on demand for registrants through 31 December 2020; offering more than 90 hours of programming content for attendees to view at their leisure. Additionally, a series of preconference sessions of approximately 50 hours of content, exclusively available to registered attendees, will be accessible on demand beginning 14 October 2020. The ISPOR Short Course Program is now being offered virtually with a wide variety of course topics provided to enhance knowledge and techniques in core HEOR topics as well as emerging trends in the field. Virtual courses are posted here as they become available.
ISPOR is recognized globally as the leading professional society for health economics and outcomes research and its role in improving healthcare decisions. Virtual ISPOR Europe 2020 will draw healthcare stakeholders with an interest in HEOR, including researchers and academicians, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers, and patient engagement organizations.
Additional information on the conference can be found at: Conference Information | Program | Registration Information | Short Course Program | Exhibits & Sponsorship | Press
###
ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website | LinkedIn | Twitter (@ispororg) | YouTube | Facebook | Instagram
